Immunotherapy targeting programmed cell death protein 1 (PD-1) or its ligands, programmed death ligand 1 (PD-L1) can improve the survival of BLCA patients, but not all patients respond to this kind of therapy (21). This evidence concerns the gene PDCD1 and bladder transitional cell carcinoma.